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Introductory note 
 
Prescribing is a major clinical activity and a key therapeutic tool for influencing the health of patients. 
When certain psychoactive drugs are inappropriately prescribed there is potential for patients to 
become dependent or suffer withdrawal symptoms, leading to a range of health and social harms. 
The prescription of a number of these drugs continues to rise mainly because of longer term use, and 
this issue is becoming increasingly ingrained with complex medical, political and ethical challenges. 
Too little is known about prescribing patterns, the levels of dependence and withdrawal, and the 
level of harm that is being caused. There is also too little research about the long-term effects of 
these drugs. 
This analysis report has been developed following the board of science’s call for evidence undertaken 
in March 2014. It aims to provide a platform for action to improve the prevention, identification and 
management of dependence and withdrawal associated with prescribed drugs, and has a particular 
focus on the prescribed use of benzodiazepines, z-drugs, opioids and antidepressants.  
In undertaking this project, it was clear from the outset that this subject was contentious and 
emotive. It is characterised by a mistrust of the medical profession, government and policy makers 
by those affected, who describe meeting a denial of the problem and too little help from their 
doctors. It was also apparent that any constructive dialogue on how best to address this problem was 
being prevented by a wide spectrum of differing views. That is why we took the approach of a call for 
evidence, to allow us to hear all viewpoints, however conflicting they may be. Despite this, some 
individuals and organisations declined to participate.  
I ask that you keep this in mind when considering our analysis. It is not intended to provide a 
systematic review of the evidence, or to pass judgement as to whether the views expressed are valid. 
This document sets out the ‘state of play’ on what the issues are considered to be, where there is 
common ground between stakeholders, and where there are differences of opinion. It does not 
represent the BMA’s view about what needs to change, as I believe it is important for this 
Association to work with all stakeholders to develop an improved policy framework. 
My hope is that the themes we have identified will help to support a collaborative approach moving 
forward. This means that, while you may not agree with everything presented here, I am asking you 
to recognise that there are significant differences of opinion and to consider how they can be 
overcome. Take for example the use of the term ‘involuntary dependence’, which we originally 
proposed for the title of this project, and for which we have been praised and criticised in equal 
measure. While I understand this strikes at the heart of this issue for many, it is vital that the debate 
about terminology does not detract from working collaboratively.  
We must also not derail progress by focusing on where blame may lie. Instead we need to consider 
what positive action can be taken for the future benefit of patients, through recognising and treating 
the genuine problems associated with withdrawal, and importantly ensuring compliance with 
treatment guidelines.  
Some of you may think this report is too little, too late. I ask that you see it as an opportunity to 
engage with the BMA on this significant area of concern. Whether as patients, doctors, service 
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commissioners or policy makers, I believe we all have the same goal of ensuring patients benefit 
from and are not harmed by the medications they are prescribed. 
 
Professor Sheila the Baroness Hollins  
Board of science chair  
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Background 
In March 2014, the board of science sent out a call for evidence in the form of an open ended 
questionnaire seeking information and views from a range of key stakeholders (see Appendix 1). 
Questions were focussed on prescription drugs with an established dependence potential 
(benzodiazepine, opioids and Z-drugs) and withdrawal effects (antidepressants). Those contacted 
included professional and governing bodies, charities and support organisations (see Appendix 2). 
Through contacting a wide range of stakeholders, the project aimed to collate a diverse range of 
views that reflect some of the ‘real-life’ barriers to addressing dependence to prescription medicines. 
A number of withdrawal charities and support groups not contacted directly also submitted 
evidence. These submissions were included in the analysis to maintain an inclusive approach of views 
and information relevant to this topic.  
Data analysis 
Evidence submitted was analysed using an inductive thematic analysis. This model of analysis 
systematically reviews overarching patterns (themes) within qualitatively rich data. The ‘inductive’ 
component of this analysis involves searching for themes in a data driven, or ‘bottom-up’, manner. 
This approach is employed in exploratory research designs when no specific hypothesis has been set 
prior to data collection. As the principal aim of this project was to collate information from a range of 
stakeholders – with no specific hypotheses set prior to data collection – an inductive method was 
chosen to allow outcomes to be guided solely by data submitted and not pre-existing hypotheses. 
Procedurally, this analysis was conducted through systematically applying ‘codes’1 to a data set, 
followed by an analysis of all codes into overarching patterns (themes). Further details of the analysis 
can be found in Appendix 3. 
  
                                                          
1 The most basic segment, or element, of raw data or information that can be assessed in a meaningful way 
regarding a phenomenon. 
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Results 
A total of 26 responses were received to the call for evidence, including 17 from the 38 stakeholders 
contacted directly, and nine from additional organisations and individuals not contracted directly. Of 
the total 26 responses received, six did not submit evidence, leaving 20 submissions to be analysed. 
There were 17 submissions that consisted of qualitatively rich ‘codable’ data that were analysed in 
group one, and five submissions of ‘non-codable’ data (eg peer-reviewed journals, guidance and 
webpages) that were analysed in group two. A submission from NHS Greater Glasgow and Clyde 
Addictions Services consisted of a qualitative response analysed in group one and guidance analysed 
in group two.  
Overall, submissions focussed heavily on benzodiazepines, with 16 substantial responses submitted 
on this drug group. Nine submissions discussed Z-drugs and opioids, and six submissions discussed 
antidepressants. For summaries of this information, see Tables 1 and 2. 
Table 1: Descriptive statistics on evidence submitted and break down of submission by drug group 
 
  
Measure Quantity 
Number of submissions 26 
Number of submissions to be analysed 20 
Phase 1 responses 17 
Phase 2 responses 4 
Drug group submissions 
Benzodiazepine 16 
Z-drug 11 
Opioid  11 
Antidepressant  7 
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Table 2: Summary of all submissions by organisation, type of submission, analysis and drug group. 
BDZ = benzodiazepine; AD = antidepressant 
  
Organisation Submission type Analysis 
group 
Drug group included 
All Party Parliamentary Group for 
Involuntary Tranquilliser Addiction 
Decline - - 
Battle Against Tranquillisers Questionnaire 1 BDZ 
Bristol and District Tranquilliser Project Questionnaire 1 AD, BDZ 
Committee of General Practice 
Education Directors 
Decline - - 
Conference of Postgraduate Medical 
Deans of the United Kingdom 
Decline - - 
Council for Evidence-based Psychiatry Questionnaire 1 AD, BDZ, Z-drug 
Council for Information on 
Tranquillisers, Antidepressants, and 
Painkillers 
Questionnaire 1 AD, BDZ, Opioid, Z-
drug  
Faculty of Pain Medicine of the Royal 
College of Anaesthetists 
Journal articles 
Short summary 
2 Opioid 
General Medical Council Decline - - 
Oldham Tranx Decline - - 
Public Health England Questionnaire 1 BDZ, Opioid, Z-drug 
Recovery Road Questionnaire 1 AD, BDZ, Opioid, Z-
drug 
REST (Mind in Camden) Questionnaire 1 BDZ, Z-drug 
Royal College of General Practitioners Questionnaire 1 AD, BDZ, Opioid, Z-
drug 
Royal College of Psychiatrists Questionnaire 1 AD, BDZ, Opioid 
Royal Pharmaceutical Society Questionnaire 1 Opioid 
Substance Misuse Management in 
General Practice 
Decline - - 
Anonymous Self Help Group Questionnaire 1 BDZ, Z-drug 
BenzoBuddies Questionnaire 1 BDZ, Z-drug 
NHS GGC Managed Clinical Network for 
chronic pain 
Guidelines 
Short summary 
2 Opioid 
NHS GGC & Addictions Guidelines, 
Standards and 
webpages 
Long summary 
2 
 
 
1 
AD, BDZ, Opioid, Z-
drug 
Royal College of Physicians Short summary 2 Opioid 
Catherine Pittman Questionnaire 1 BDZ, Z-drug 
David Dicks Questionnaire 1 BDZ, Z-drug 
Heather Ashton Long summary 1 BDZ, Opioid 
Howard Wingfield Questionnaire 1 BDZ 
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Summary of themes 
The following provides an overview of the main output themes and subthemes. For individual themes 
per submission response please see Appendices 4 and 5. 
Theme 1: Benzodiazepine prescribing and management of prescription benzodiazepine 
dependence and withdrawal in general practice 
Subtheme 1a: 
Managing benzodiazepine dependence and withdrawal in general practice 
Loading themes 
 Tapering protocols  
 Patient support  
 GP training  
 Withdrawal guidelines 
Responses that submitted evidence on benzodiazepines reported a significant problem in the 
management of prescription benzodiazepine dependence and withdrawal in general practice. The 
most common example of suboptimal management was the use of rapid tapering or ‘cold turkey’ 
cessation protocols by GPs. It was reported that patients often turn to benzodiazepine support 
groups or withdrawal charities as a result of being placed on a rapid tapering or termination schedule 
by their GP. For example, the withdrawal charity REST (Mind in Camden) noted that “…some GPs 
appear to underestimate the dependency to benzodiazepines and impose unrealistic time scales on 
the tapering process. Over rapid withdrawals is something that our clients consistently complain 
about.” From a broader perspective, Recovery Road reported that the worst cases of withdrawal 
they have “…witnessed are those where patients have been taken off their medication abruptly or 
rapidly in detoxification facilities.”  
These responses – in combination with those from the RCPsych (Royal College of Psychiatrists) and 
individuals affected by benzodiazepine dependence – emphasised that the rate of withdrawal 
tapering should be gradual and flexible around the patient. There was agreement that withdrawal 
tapering should not be fast or fixed as this approach can initiate severe and intolerable withdrawal 
symptoms that are not typically associated with gradual dose reductions.   
Responses that discussed fast tapering schedules highlighted over-arching concerns about rapid 
tapering protocols that are enforced against patient wishes, and withdrawal management not being 
patient centred. Submissions from charities, support groups and individuals affected by 
benzodiazepine dependence noted that patient consent often is not gained before initiating fast 
tapering, and patients may not be consulted or involved in the decision to taper or terminate their 
medication. For example, an anonymous self-help group reported that “…many doctors reduce the 
dose at a rate that is not tolerable for the patient, or they simply stop their benzodiazepine treatment 
without their [the patient’s] informed consent…” and that “…doctors frequently make decisions 
[about benzodiazepine tapering] without reaching an agreement with the patient on their 
treatment.” 
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Consistent with this, many of the submissions from withdrawal charities and support groups 
indicated that patients can feel unsupported and abandoned by their doctor when dependence is 
identified. CEP (the Council for Evidence-based Psychiatry) submitted evidence from a small-scale 
survey – conducted with patients in the UK affected by prescribed drug dependence – which found 
that 71 per cent of respondents (n=50) reported feeling unsupported by their prescribing doctor 
once dependence was identified. BenzoBuddies also reported that “[a] supportive GP is of great 
importance; most are not so fortunate. Moral and emotional support is one thing, and although 
BenzoBuddies and similar groups might offer some practical tips, real-world, practical support is 
required. Too often dealing with an unsympathetic GP is yet another hurdle to overcome.” CITA (the 
Council for Information on Tranquillisers, Antidepressants, and Painkillers) noted that “[p]hysician 
initiated withdrawal decisions involve stopping medication abruptly, refusing to supply the next due 
script, leaving their patient in severe withdrawal, with instructions to find their own way to a street 
drug unit. This the patient does only to be told that the drug unit does not deal with prescription 
drugs and they are sent away or back to the GP who refuses to help.” 
This issue was also discussed on a number of occasions in the RCGP (Royal College of General 
Practitioners) submission, providing insight from the GP perspective. The RCGP reported that it can 
be extremely difficult for GPs to achieve jointly agreed withdrawal plans when there is a conflict 
between the clinical legitimacy of prescribing and a patient’s reluctance to reduce their dose. In this 
circumstance, the GP is conflicted by their medical duty not to prescribe without a clear indication 
for the medication, but also to support the patient and to gain their consent to tapering plans. As a 
result, this can involve difficult conversations between GPs and patients that can strain the doctor-
patient relationship: “...generally [patients] don’t agree with treatment that reduces their prescribed 
medication. This may damage the doctor patient relationship when the patient’s medication is 
stopped, reduced or changed largely against their wishes; even if the doctor explicitly states they can 
no longer justify prescribing the original medication at the original doses.” This highlights a particular 
area of need in supporting GPs to manage the complexities of gradual dose reductions while 
maintaining patient confidence and trust that it is in their best interests.  
One of the main barriers to achieving appropriate GP-led withdrawal protocols was reported to be 
limited knowledge and training for GPs on prescription drug dependence. This was highlighted in 
submissions from withdrawal charities and support groups, and echoed in the RCGP and RCPsych 
submissions. The RCGP reported that many GPs may feel they lack the knowledge, experience and 
confidence to manage prescription drug dependence in general practice. They discussed the impact 
of limited training on successfully implementing an agreed tapering plan: “[p]ersuasion and achieving 
a jointly agreed [tapering] plan may take time, effort and skills that many general practitioners feel 
they would need additional training to achieve.”  
Withdrawal charities and support groups also noted that limited training can mean that GPs 
underestimate the severity of benzodiazepine withdrawal. For example, the Bristol & District 
Tranquilliser Project reported that “[m]ost doctors do not understand either the severity or duration 
of withdrawal symptoms caused by benzodiazepines…or the length of time it takes to recover post-
withdrawal. It seems that they receive little to no training in this area, something that desperately 
needs to be remedied.” Response submissions from these groups often reported that GPs do not 
recognise the distinction between prescription and illicit drug dependence, and therefore apply 
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withdrawal protocols commonly used for illicit drug treatment withdrawal, such as rapid tapering 
and ‘cold turkey’ cessation. CITA noted that, “…many GPs do not understand the difference between 
the involuntary and chemical addiction engendered by prescription drugs and the predominantly 
psychological addiction from street drugs and alcohol. These latter can be withdrawn very quickly and 
subsequent discontinuation symptoms last only a few weeks. Hence such addicted individuals are told 
to get rapidly “clean” and drug free before they will be seen and helped.  This is very different from 
scripted drugs which require slow reduction over many months, following which there is a prolonged 
recovery period initially of biochemical and physiological recovery but then a longer recovery of the 
functions lost during their years on their medication.”  
Issues surrounding clinical guidance on prescription benzodiazepine tapering were also reported by a 
number of submissions as a further barrier to achieving appropriate withdrawal management. Both 
the RCGP and RCPsych reported a lack of robust evidence-based clinical guidelines on best practice 
withdrawal management. In relation to treatment options, the RCGP noted that “[w]e are not aware 
of any good research to guide which is the most effective approach or how effective each approach is, 
despite widespread opinion…” The RCPsych noted that treatment is “[c]urrently poorly managed due 
to lack of appropriate clinical guidelines and training.” The RCPsych also highlighted that a clinical 
guideline on how to manage prescription drug dependence, distinct from illicit dependence, is 
urgently needed: “[t]he most useful thing to come out of this review is a call for a NICE guideline on 
management of prescription drug abuse and dependence, with a systematic review of the evidence 
and clinical guidelines for all healthcare professionals”.  
In contrast, submissions from withdrawal charities and support groups reported that there are 
existing guidelines available that can, and should, be used more frequently by GPs when supporting 
patients to withdraw. These guidelines included the Ashton Manual, BNF (British National Formulary) 
and NICE CKS (clinical knowledge summary). There were, however, mixed views between responses 
regarding which of these guidelines is best practice. Some submissions reported the Ashton Manual, 
or close variations of this schedule, as best practice for benzodiazepine tapering, with CEP noting 
that “…most of the withdrawal charities follow the tapering protocols outlined in the Ashton 
Manual.” In contrast, one anonymous support group reported the Aston Manual to be overly rigid 
and structured and not appropriate as a clinical guideline: “[the Ashton Manual]…confuses both 
patients and doctors and makes benzodiazepine withdrawal far more difficult than it needs to be”. 
Other submissions referenced the BNF and NICE CKS as best practice guidelines on prescription 
benzodiazepine withdrawal, and some noted all three can be used as best practice. For example, 
REST reported that “[w]e use the Prof Ashton manual, NICE guidelines, latest BNF guidelines to 
inform the withdrawal advice given.”  
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Subtheme 1b: 
Long-term prescribing of benzodiazepines outside of clinical guidelines 
Loading themes 
 GP knowledge on the harms of long-term prescribing 
 Patient information on the risks associated with benzodiazepines  
 Safeguards to monitor inappropriate prescribing 
 Availability of non-pharmacological treatment options 
 Prescribing without clear clinical indication 
 Patient pressures 
As highlighted by CEP, an overarching view expressed by withdrawal charities and support groups 
was that “[m]any of the patients experiencing problems with prescribed medicine would have avoided 
the associated harms if their doctors had simply adhered to the prescribing guidelines.” This 
comment was made mainly in relation to benzodiazepines and to GP prescribing, but also sometimes 
in relation to prescribing by psychiatrists.  
Various submissions highlighted that BNF guidelines – which indicate the use of benzodiazepines for 
a period of two to four weeks maximum (including tapering) – are appropriate and safe for patients 
suffering severe and disabling anxiety. However, nearly all of these submissions went on to note that 
in practice BNF guidelines are rarely followed. Responses were therefore largely in agreement that 
benzodiazepines are safe and beneficial when prescribed within recognised clinical guidelines but 
there is a significant issue surrounding prescription outwith of these guidelines. One withdrawal 
charity BAT (Battle Against Tranquillisers) suggested that the upper limit for prescribing be reduced 
to a maximum of two weeks (including tapering) in an attempt to reduce the harm caused by long-
term prescribing. 
Explanations for why long-term benzodiazepine prescribing outside of guidelines occurs varied across 
responses. Withdrawal charities and support groups reported that it can happen when GPs have 
limited knowledge of the harms associated with this long-term pattern of prescribing. For example, 
there was particular concern raised about benzodiazepines that are prescribed with the instruction 
to take ‘as and when necessary’. This type of irregular use was not reported safe as it can foster 
uncontrolled use of benzodiazepines and sporadic withdrawal symptoms. It was also noted that 
benzodiazepines can be prescribed with the explicit instructions to take regularly and long term. 
There was particular concern raised about patients being informed they will need to take 
benzodiazepines long term because of the nature of their mental illness. For example, a submission 
from an individual affected by prescribed benzodiazepine dependence reported they were 
prescribed benzodiazepines regularly after being told by their psychiatrist that “…like a diabetic 
needs insulin…” they would always need to take benzodiazepines because of their anxiety.  
Issues surrounding patient information and patient-centred care when prescribing benzodiazepines 
emerged as a common theme in many submissions from withdrawal charities and support groups. 
This reflected concerns that patients are not adequately informed of the harms and risks associated 
with benzodiazepines, and that patient consent to begin a course of benzodiazepines, based on an 
understanding of these harms/risks, often is not gained. It was reported that patients often are not 
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informed that benzodiazepines will cause withdrawal symptoms, or that they may cause dependence 
when taken long term. Some patients may also be misinformed that benzodiazepines do not cause 
dependence at all because they are prescribed for a mental health problem rather than taken 
recreationally. The following quote is from an individual who developed withdrawal symptoms and 
dependence from prescribed benzodiazepines for brainstem myoclonus:  
“As I recall, it was about 4 months after my final dose (May, 2003) when I began to 
research online to see if others experienced similar [withdrawal] problems. Before 
these searches, I did not even realise that the ‘anticonvulsant’ (Rivotril) was related to 
Valium and Mogadon (both of which I had vaguely heard of as psychiatric 
medications). I had never heard of ‘benzodiazepines’. I had no personal experience of 
psychiatric medications, nor was I aware of anyone within my family or circle of friends 
who were prescribed this class of drugs. Except for my previous attempts at 
withdrawal, I had no expectation or knowledge of side effects or withdrawal symptoms 
I might experience.” 
Many of the responses that discussed benzodiazepines also identified poor monitoring systems in 
general practice as a cause of long-term prescribing. This was related to inadequate doctor-led 
(through ensuring regular review of patients initiated on benzodiazepines) or IT-based monitoring (to 
identify automatic repeat prescriptions for benzodiazepines). For example, BAT identified updating 
general practice IT systems – to flag repeat benzodiazepine prescriptions and courses of 
benzodiazepines that exceed three weeks – as a key area for action to tackle the problem of long-
term prescribing. While this would require some significant investment, the charity noted that this 
would be a practical step towards reducing the unnecessary distress caused to patients and families 
by long-term prescribing. 
The under-funding and poor availability of non-pharmacological therapies were also identified as 
contributory factors to long-term prescribing. There was agreement between responses from 
withdrawal charities, support groups and medical organisations that better availability of 
psychological therapies would reduce the need for the over prescription of benzodiazepines. For 
example, CEP noted that “…the IAPT [Improving Access to Psychological Therapies] programme has 
established that there is a very high demand for non-pharmacological approaches. Indeed, supply of 
such provision cannot yet meet demand – hence the investment in the IAPT programme and, 
presumably, the use of harmful pharmacological alternatives.” The RCPsych reported that “…the 
availability of psychological interventions is currently limited. Therefore one can understand a busy 
practitioner’s tendency to prescribe rather than refer for psychotherapy when there is a drug that will 
effectively alleviate symptoms in the short term.”  
The RCGP and RCPsych both raised the issue of prescribing without clear clinical indication in relation 
to long-term prescribing. Both Colleges discussed how the impact of patient pressures, particularly 
when combined with the lack of available alternative non-pharmacological treatment options, can 
lead to GPs inadvertently prescribing benzodiazepines outside of guidelines, even under 
circumstances where the GP feels the prescription may not be justified. This can lead to a situation 
where a patient is prescribed benzodiazepines outside of the four week guideline without a clear 
clinical indication for the medication, which may then subsequently continue long term and across 
different practices and GPs.  
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Considering this point further, the RCPsych touched on the difficulties a GP may have when a patient 
puts pressure on them to prescribe while concealing their full use, so that their prescribing doctor is 
unaware they are inappropriately prescribing in the first place. The RCPsych noted that “…patients 
may seek prescriptions from multiple different doctors to conceal the full extent of their dependence 
on medications…” and that they “…may use multiple pharmacies to avoid suspicion of over use.” The 
RCPsych also noted the problem of diversion and the impact this has on driving patient demand and 
pressures for benzodiazepines. They highlighted that, “[t]here is a job for enforcement to look at 
ways to stem the illicit market in these drugs which is likely to stoke demand for prescriptions.” 
A focus on: Z-drugs 
Although discussed to a much lesser extent to benzodiazepines, the increasing and over prescribing 
of Z-drugs was highlighted as a growing area of concern, with withdrawal charities and support 
groups reporting seeing more people addicted to these medications.  
As with benzodiazepines, the RCGP noted that Z-drugs “...can be initiated legitimately and may be 
continued inadvertently, either in response to patient request or when monitoring is interrupted, or 
inconsistently applied leading to tolerance and in some cases addiction.” Similarly, CITA highlighted 
that Z-drugs “…are frequently prescribed as a cure for insomnia rather than a temporary remedy and 
maintained on prescription for too long, by which time addiction has resulted.”  
Responses from withdrawal charities and support groups highlighted a number of other concerns in 
common with benzodiazepines, including that: 
- abrupt termination of treatment/rapid tapering can elicit severe and intolerable withdrawal 
symptoms 
- most withdrawal charities follow the tapering protocols outlined in the Ashton Manual, although 
some believe that even these taper rates are too fast 
- many patients were reporting not being supplied with any information when prescribed Z-drugs, 
or were misinformed that they do not cause addiction or dependency. 
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Theme 2: Governance and service provision for patients suffering with prescription drug 
dependence and withdrawal 
Loading themes 
 Lack of specialised services 
 No mandatory provision of services 
 Poor central governance  
 Inadequate funding 
Nearly all responses reported that there is a gap in the provision of appropriate and specialised 
services for those suffering with dependence to prescribed drugs. Isolated examples of appropriate 
services were reported in certain parts of England, but it was noted that these were only 
commissioned as a result of substantial lobbying from local support groups and patient advocates, 
rather than a co-ordinated national strategy. As Recovery Road noted, “[t]here is no provision, 
recognised standard of treatment, or appropriate service for involuntarily dependent individuals as 
evidenced by the demand for the services of the withdrawal charities.” The RCPsych went into more 
detail by stating that it is clear that “…this population in recent years has not been seen as a 
commissioning priority and as a result tends to fall between addiction services which are 
commissioned to deal with severe end of illicit drug and alcohol dependence and general psychiatry 
which has moved more towards severe mental illness. Such patients are often excluded from IAPT 
services by virtue of their drug dependence, although there will be some exceptions to this. Often the 
burden of care falls on the GP who will be ill equipped to manage such patients.” 
A central aspect of these concerns was that prescription drug dependence requires distinct 
treatment approaches to illicit dependence, and therefore distinct treatment services. Patients with 
prescription dependence may be referred to drug treatment services that are tailored to illicit 
dependence, and which do not have the resource, training or skills to manage prescription 
dependence. With the exception of the RCGP, there was a large consensus among responses that 
illicit drug treatment services are not appropriate for the management of prescription drug 
dependence. The distinction between treatment approaches for illicit versus prescribed dependency 
was mainly discussed in regards to the speed of tapering required, but also the differences in 
pathways to dependence, and consequently the psychological influences on developing dependence. 
For example, BenzoBuddies highlighted that people wishing to discontinue their prescribed use of 
benzodiazepines “…are either left to their own devices (no real-world support), or they are offered 
support services developed for those who have become ‘addicted’ through illicit drug use. Such 
programmes are meant for those who participate in a set of behaviours associated with ‘addiction’, 
not those who have taken their doctor-prescribed medications as instructed. Instead, the involuntarily 
dependent deserve and require access to support tailored to their particular needs.” As CITA 
explained, this was not a criticism of the existing addiction services, but a view that they do not meet 
the needs of this patient group: “The acknowledged expertise of such agencies and units in their 
established fields is without question, but it is CITA’s experience that such agencies do not understand 
the different nature of prescription medicine addiction and either refuse to see or deal with such 
patients, or initiate a rapid withdrawal along conventional alcohol or illicit drug lines which puts the 
patient into severe withdrawal, which the drug agency then struggles to understand.”  
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In addition to not being able to provide appropriate treatment for patients with prescription drug 
dependence, it was also noted that illicit drug treatment units often do not accept patients with 
prescribed drug dependence because of commissioning governance. For example, the RCPsych 
stated that “[c]urrent addiction services are not resourced to provide adequate care for this 
population, and indeed are actively dissuaded from doing so in service contracts issued by 
commissioners, rather than being led by patient demand.” As a result, treatment for those patients 
that do not have specialised services either receive inappropriate treatment for their dependence, 
such as rapid tapering, or they are turned away from these services to return to their GP, who a 
discussed under theme one, may feel they lack the skills and training to manage this type of 
dependence.  
Despite the provision of services for prescription drug dependence being reported as poor overall, 
responses did identify a number of isolated examples of good practice. These included an Oldham 
community based service, run with the support group Oldham Tranx, and The Bridge Project in 
Bradford. There was consensus among responses that the success of these services is related to the 
development of a partnership between primary care and third sector organisations that have 
specialist expertise in managing prescription dependence. Best practice was therefore reported as 
specialised prescription drug dependency services, distinct to illicit drug treatment services, which 
are centred around and run in collaboration with primary care.  
Poor central governance of prescription drug dependence was a common theme that emerged 
across submissions. Notable frustration was expressed at the lack of recognition of the scale of the 
problem by the DH (Department of Health) and government ministers, as well as the lack of action to 
address inadequate service provision. For example, responses highlighted the significant difference 
between the assertion from the DH that there was adequate local service provision in most of the 
country, and the findings of a 2012 APPGITA (All-Party Parliamentary Group on Involuntary 
Tranquiliser Addiction) survey. The latter found that, of the 100 primary care trusts who responded 
to their survey, 83 had no services available in their area to support involuntary tranquiliser 
addiction, 11 had partial services and only six confirmed that they had services.  
There was also criticism of the way in which the DH considers these services as ‘non-mandatory’, 
which puts the onus on local agencies to commission and provide services necessary to meet local 
need. CEP highlighted concern with this approach in the way it relies on local champions to lobby for 
commissioning of services, stating that those “…most likely to lobby for greater provision are those 
directly or indirectly affected by negative drug effects. But – as we have said before – many such 
people are unaware that it is the medication that has caused these negative effects, while others are 
just too ill even to contemplate such lobbying, or have no interest in revisiting the issue once they 
have recovered, given the trauma of their experience.” CEP further highlighted that the management 
of dependence and withdrawal “…requires active investigation, identification, out-reach and support 
in collaboration with GP services and other agencies. Such a pro-active approach will only occur if the 
provision of these services is made mandatory.”  
The RCGP and the RCPsych suggested it would be useful for there to be commissioning guidelines 
that detail the types and standards of treatment services that should be made available. It was 
 15 
 
unclear from their respective responses whether they were aware of the 2013 guidance2 developed 
by PHE (Public Health England) for NHS and local authority commissioners. While few responses 
acknowledged the existence of this guidance, BAT highlighted that they had recommended it to 
commissioning groups that had approached them for advice. 
Another recurrent theme in submissions was the lack of, and need for, ring-fenced funding for 
specialist services. As noted in the preceding paragraphs, this has led to an overreliance on services 
being provided by the voluntary sector, which in themselves are estimated to cover less than five per 
cent of the country in terms of the population they serve. Of particular note is the funding 
constraints on the voluntary charities – CEP reported that “[d]espite Department of Health claims to 
the contrary, the charities assert that the situation has become worse since the delegation of funding 
to local authorities. This has led to increased levels of uncertainty regarding financing, and to at least 
one charity reporting that it is at risk of closure due to changes in the local funding priorities.” From a 
broader perspective, a wider point highlighted in various responses related to the balance of funding 
for those adversely affected by the use of illicit drugs compared to those affected by dependence 
and withdrawal associated with prescribed medications. According to Professor Heather Ashton, 
“[t]he population involved – which is largely ignored by the DOH [Department of Health] – accounts 
for far more addicted users than all the misusers/abusers of illegal drugs on which the DOH spends so 
much money. Surely the DOH has a responsibility to provide services for these people?” 
    
                                                          
2 Public Health England (2013) Commissioning treatment for dependence on prescription and over-the-counter 
medicines: a guide for NHS and local authority commissioners. London: Public Health England. 
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Theme 3: Harms associated with prescription benzodiazepine dependence and withdrawal 
Loading themes 
 Type of harms 
 Magnitude of harms 
 Presence of long-term harms 
While short-term use of benzodiazepine (two to four weeks) was not reported as harmful per se, the 
potential for this to escalate into medium or long-term use and dependency was highlighted as the 
main risk of short-term use. Similarly, the harms associated with dependence and withdrawal was a 
consistent theme across submissions. This encompassed differing views on the type (physical, 
psychological and social) and magnitude of harms.  
Submissions from withdrawal charities, support groups and individuals affected by prescription 
benzodiazepine dependence emphasised the wide range of physical (seizures, headaches, 
palpitations), psychiatric (hallucinations, psychotic episodes, anxiety, panic attacks, suicidal 
intention), psychological (trauma) and social harms (loss of job, leave education, financial instability) 
associated with prescription dependence and withdrawal. By contrast, the RCGP focused mainly on 
the physical harms (acute and chronic) associated with benzodiazepine dependence, such as 
accidents and injury associated with intoxication and physical withdrawal symptoms. The RCPsych 
made more acknowledgement of the psychological and social harms associated with benzodiazepine 
dependence than the RCGP, but overall less acknowledgement of these harms than responses from 
charity, support groups and individuals affected directly by benzodiazepine dependence.  
The presence of long-term harms following benzodiazepine termination was discussed in many of the 
submissions and there was a limited consensus between responses on this issue. For example, the 
RCGP noted that, aside from the risk of relapse, the harmful effects of benzodiazepines do not 
“…appear to continue after their use has stopped…”, and highlighted a lack of evidence of long-term 
physical consequences, such as brain injury. The RCPsych also noted that there are not generally any 
health concerns when withdrawal has been appropriately managed, and that while there are claims 
of cognitive impairment, these are disputed. A number of the responses from withdrawal charities 
and support groups reported cognitive impairment to be a long-term harm for some people affected 
by benzodiazepine dependence. CEP, in particular, highlighted research about the potential risk of 
brain damage associated with the long-term use of benzodiazepines, although their response did 
acknowledge frustration at the absence of further research in this area.  
One area covered repeatedly in submissions from charities, support groups and individuals was the 
length of time people can suffer ‘protracted’ withdrawal symptoms after withdrawal completion. As 
noted by the Bristol Tranquilliser Project, “[m]ost people will have symptoms once they come off 
these drugs for at least a year…the majority will recover in their second year. But there are some who 
will take several years.” CEP highlighted the views of Professor Heather Ashton that “[f]or some 
chronic benzodiazepine users, withdrawal can be a long, drawn-out process. A sizeable minority, 
perhaps 10% to 15% develop a ‘post-withdrawal syndrome’ which may linger for months or even 
years.” An individual response from Professor Catherine Pittman enclosed the results of a research 
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project assessing dependence-related difficulties in long-term prescribed benzodiazepine users 
(n=1,000), including the measurement of the type and duration of withdrawal symptoms following 
benzodiazepine discontinuation. The study found that 96 per cent of long-term prescribed users 
continued to experience withdrawal symptoms for an average of 14 months after withdrawal and 
cessation from benzodiazepines. It was also reported that in addition to protracted withdrawal, there 
can be some enduring symptoms – such as tinnitus, anxiety, motor symptoms, gastrointestinal 
symptoms and paresthesia – which can persist for years beyond this timeframe.  
Withdrawal charities, support groups and individual submissions also placed significantly more 
emphasis on the long-term psychosocial harms associated with dependence (such as loss of 
confidence after trauma of dependence, loss of friendships and relationships, adverse impacts on 
family members, time out from studying and achieving lower grades than expected, and loss of skills 
to return to employment). The overarching theme of many of these submissions was how 
benzodiazepines can devastate a patients’ life. For example, BenzoBuddies reported that “[m]any 
long-term users of benzodiazepines become completely habituated to their altered state, a life half-
lived, unable to properly recall what it was like before benzodiazepines.”  
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Theme 4: Attitudes towards the cause of prescription drug dependence and withdrawal 
Loading themes 
 Prescription drug dependence as an iatrogenic condition 
 Moral obligations to support patients with prescription dependence 
 Stigmatising patients with prescription drug dependence 
Consideration of the cause of prescription drug dependence was an underlying theme across many 
response submissions and appeared to influence a number of key issues within the over-arching 
themes identified. 
The clearest difference in attitudes within this theme emerged between charity, support groups, 
individual responses and the RCGP. Responses from the former repeatedly raised the point that 
individuals affected by prescription dependence would not be dependent if doctors did not 
inappropriately prescribe in the first place. While these responses acknowledged additional 
contributory factors, fundamentally there was a strong view that accountability for the transition 
into prescription dependence lays with the medical profession. By contrast, the RCGP noted a 
number of points that aligned with the view of transition into prescription drug dependence largely 
resulting from individual differences in patients, rather than prescription patterns or drug harms. For 
example, the RCGP stated that: 
“[t]here is a small proportion of patients who become addicted to such medication 
[benzodiazepines, Z-drugs and opioids] and continue to use them for reasons other than 
relief of the underlying condition. This may be for the euphoric effects or to avoid 
withdrawal symptoms on reducing or stopping... Why some people become addicted with 
prolonged use of these medications and not others is also not clear, though it is likely to 
depend on personal and social factors. Patients who become addicted are more likely to 
have the following features: associated chronic physical and or mental health problems, 
chronic physical and mental illness unresponsive or relatively unresponsive to other 
treatment approaches, a past history of dependence to prescribed or illegal drugs, social 
and cultural factors that encourage ongoing prescribed drug use.” 
An individual submission from Professor Catherine Pittman also touched on this theme by reporting 
the results of research assessing dependence-related difficulties in long-term prescribed 
benzodiazepine users. Her research found no difference in the emergence and experience of 
withdrawal symptoms between those individuals prescribed benzodiazepines for psychiatric versus 
non-psychiatric (eg seizures, muscle tension, recovery from surgery) conditions. This suggests that 
long-term exposure to benzodiazepines per se may account for the severity of withdrawal 
experienced by prescribed users, and subsequently difficulties terminating use, rather than pre-
existing individual differences in mental health status. 
Charity, support groups and individual submissions expressed strong views that dependence was 
iatrogenic in that it was caused directly from long-term, inappropriate prescribing. For example, one 
individual submission explained their experience of learning that the symptoms they had while taking 
long-term prescribed benzodiazepines were not due to their anxiety but due to their benzodiazepine 
prescription:  
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“On one of my frequent visits to see her [the GP] she shocked/frightened me. She said that 
she thought the medication I was taking was causing my problem not me. SOMETHING NO 
other medical person had said. ALL the others had said I was the problem and that the drugs 
were giving me a life.” 
The RCPsych did not explicitly state that prescription dependence is an iatrogenic condition but did 
note that inappropriate prescribing of benzodiazepines leads to dependence: “In relation to 
benzodiazepines many patients are encountered who have received long term, high dose 
prescriptions, outside of guidelines and normal indications for these drugs, resulting in long term, 
chronic dependence on benzodiazepines.”  
Differences in views on the cause of dependence also overlapped with differences in views on the 
type of treatment services that should be available for this patient group. As discussed in relation to 
Themes 1a and 2, charity, support groups and individual submissions all noted that services for this 
type of dependency should be separate to services for illicit drug use. In contrast, the RCGP noted 
that they see “…no reason why this should not be similar to services for treatment for dependence to 
illegal drugs’. Although the RCPsych did not make a clear indication about what they consider to be 
the lead cause in the development of prescription dependence, they did state that addiction services 
are ineffective for treating this patient group and that separate services should be provided for 
prescription drug dependency. 
In connection with the view that prescription drug dependence is largely an iatrogenic condition, 
these groups strongly expressed the opinion that doctors and the NHS have a moral obligation to 
support patients that develop dependence to their prescribed medicines. For example, CEP noted 
that they agree “…with other interested parties that it is a serious and costly failing that there is no 
nationwide provision of services for prescribed drug withdrawal, particularly given the moral 
obligation to help individuals who have become dependent predominantly through NHS GP 
practices.” This attitude appeared to relate to a number of emotive attitudes towards the lack of 
action being taken by governing bodies on this topic. It also relates to the discussion under Theme 2 
about the lack of parity in the funding for services for those affected by illicit drug use compared to 
this patient group. Reference was also made to the rights patients have under the NHS Constitution, 
in particular in relation to involvement in discussions and decision about your own healthcare. For 
example, BAT noted examples of patients who have been prescribed benzodiazepines over a long 
period being told they are going to stop the prescriptions, and that "[t]he most common phrase that 
accompanies these discussions is ‘this is not negotiable’ which goes against the NHS Constitution...". 
A further aspect highlighted in responses was how this patient group is often stigmatised. As 
Professor Heather Ashton notes, “…those who had been prescribed such [psychotropic] drugs by their 
doctors for anxiety or pain, did not misuse other drugs, but had unknowingly become iatrogenically 
dependent because of long-term misprescriptions. This group were also stigmatised as misusers 
although they were simply compliant with their doctor’s advice.” While it could be argued that this 
view in itself stigmatises illicit drug users, a key concern was that patients affected by prescription 
drug dependence may be less likely to engage with addiction services, or may suffer because of 
discriminatory attitudes of medical professionals and in wider society.  
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It is worth noting that this theme is more implicit than others presented. It emerged as a key over-
arching theme because it centres on a point of tension that ran through nearly all responses received 
from withdrawal charities, support group and individuals affected by prescription drug dependence. 
This was the reported feeling of frustration among those affected by prescription drug dependence 
towards the medical profession for blaming their patients for the development of dependence to 
their prescription medicines. 
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Theme 5: Research and data on prescription drug dependency and withdrawal 
Loading themes 
 Prevalence of prescription drug dependence 
 Effects of long-term prescribing 
 Best practice withdrawal protocols 
The urgent need for data on the prevalence of prescription drug dependence was clearly highlighted 
in submissions, with particular reference to benzodiazepines, but also in relation to Z-drugs, opioid 
analgesics and antidepressants. While the number of benzodiazepine prescriptions made in primary 
care can be monitored, the number of these that are repeat long-term prescriptions (and represent 
dependent individuals) is unknown. Estimates provided in the submissions were between 1-1.5 
million dependent users, although this was noted to be based on old data. A potential way to start to 
collect these data was suggested by Professor Heather Ashton: “…more accurate information on 
benzodiazepines and other drugs, including the indications for scripts, dosages, frequency, length of 
use, symptoms and other data, is available from the GP research data base (GPRD) which has 3 
million patient records from 400 primary care UK practices.” It is also worth noting that King’s College 
London is conducting a European Commission-funded study of prescription drug misuse which will 
include consideration of its prevalence. In relation to antidepressants, various submissions noted 
estimates of up to four million people taking them in the UK at any one time; however CEP called for 
more research to quantify this, to assess prevalence among different patient groups, and to provide 
information on the duration of treatment to establish the number of long-term users.   
CEP also strongly advocated more research into the effects of long-term prescribed drugs, 
particularly into the possibility of long-term brain damage: “While there is lot of testimony from 
individuals who have been harmed by these drugs there has been very little research. In particular, 
the following questions need answering: What percentage of patients is affected by negative & 
withdrawal effects, and how does this correlate with dosage, length of use and withdrawal method? 
What are the dangers of long-term use of these drugs? Can they cause permanent neurological 
damage?” The need for this research into long-term harms, particularly around neurological damage, 
reflects the inconsistent views on this aspect previously highlighted under Theme 3.  
A broader theme identified across submissions was the need for more research into best practice for 
identifying and managing prescription drug dependence and withdrawal. The RCPsych highlighted 
“…a lack of research and development in this area in recent years with an increasing emphasis on 
illicit drug misuse…” and noted that “[o]ptimal methods of withdrawal and management of 
benzodiazepine dependence need to be better researched and clarified. In relation to prescribed and 
OTC [over-the-counter] opioid dependence the methods are as for illicit opioid dependence, but again 
this has not been seen as a priority patient population in recent years.” The RCPsych also submitted a 
CMS (Committee on Safety of Medicines) report on the safety of antidepressants which recommends 
that research into the most effective methods of SSRI (selective serotonin reuptake inhibitors) 
withdrawal is conducted. 
The RCGP highlighted two approaches for reducing the addictive use of prescribed medication 
without causing or increasing over-the counter or illicit substitute drug use (either a structured 
reduction programme, substitute medication or a combination of the two), but noted that there is a 
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lack of research to guide the best approach, or how effective each approach is. They also indicated 
that there is a lack of research into the use of non-pharmacological treatments in this context.  
 23 
 
Theme 6: Opioids prescribed for chronic non-cancer pain 
Loading themes 
 Opioid prescribing for chronic pain 
 Safety and efficacy of opioids for chronic pain 
 Guidance on chronic pain management 
Responses that discussed opioids raised concerns about the rising levels of opioid prescriptions for 
chronic non-cancer pain, and indications that the associated harms are increasing. It was generally 
recognised that prolonged exposure to and increasing doses of opioids can lead to the development 
of tolerance and dependence. With dependence, withdrawal symptoms were noted to be severe and 
disabling. The fact that tolerance is rapidly lost when opiate use is discontinued was highlighted 
because of the increased risk of overdose with reinstatement, particularly when taken in 
combination with alcohol. 
The RCGP reported that national prescribing data suggest an increase in prescribing of opioid 
medication, and BAT observed that “…they are becoming progressively widely over-prescribed.” The 
RCP highlighted their “…concerns regarding the prescribing of opioids for chronic non-cancer pain as 
there is some evidence to suggest that prescription opioid misuse and addiction among chronic pain 
patients are emerging public health concerns.” They submitted research showing that an estimated 
10 per cent of chronic pain patients in the US misuse opioid analgesics, and the number of fatalities 
related to nonmedical or inappropriate use of prescription opioids is climbing. The NHS Greater 
Glasgow & Clyde Addiction Services also highlighted that “…in the United States there are more 
opioid related deaths now which involve an opioid analgesic than there are which involve, for 
example, heroin. In association with this we would seek to highlight the increasing problem with 
dependence on ‘Over The Counter’ (OTC) medications.” Similarly, the Greater Glasgow and Clyde 
Managed Clinical Network for chronic pain management services noted “…a reported increase in the 
number of deaths associated with prescribed analgesics in particular opioids and there is a real risk of 
morbidity being caused or of mortality, especially when there is poor compliance, alteration of doses, 
switching of analgesics or co prescription of benzodiazepines or the use of alcohol.” 
Despite widespread prescribing, the safety and efficacy of long-term prescribed opioids for chronic 
non-cancer pain was reported to be unknown. The RCP submitted some research based on the views 
of a multidisciplinary expert panel convened by the Pain Association of Singapore. This highlighted 
that there is weak evidence for the long-term use of opioids, and moderate evidence for the short-
term benefit of opioids in certain conditions associated with chronic non-cancer pain. The panel did 
not recommend the use of opioids as first-line treatment for various chronic non-cancer pain, 
restricting their use to second or third-line treatment, preferably as part of a multimodal approach. 
This theme emerged in relation to pain being a multifaceted problem and therefore needing a 
multifaceted approach to treatment, whereby opioids constitute part of the solution in the short 
term. Linked to this, the RCGP and the Greater Glasgow and Clyde Managed Clinical Network for 
chronic pain management services highlighted a general lack of availability and therefore an inability 
to refer patients for alternative approaches to pain management (eg physical therapy, psychological 
therapy, specialist pain clinics etc).   
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Responses broadly noted the existence of adequate guidance for opioid prescribing but that this is 
not always followed. For example, while the Faculty of Pain Medicine have published guidance (in 
collaboration with a number of other organisations) on the appropriate use of opioids, they reported 
“…that guidelines in the UK and elsewhere have had little, if any impact on opioid prescribing trends 
and may have the unwanted effect of falsely reassuring prescribers and eroding sound patient-
centred clinical decision making.” This matched the view of the RCPsych that many patients are 
prescribed long-term high doses of opioid analgesics "...where there is a lack of a clear clinical 
indication, although the drugs may have been prescribed initially for a legitimate clinical indication. 
There is also a significant problem of abuse of over-the-counter (OTC) opiate medications, notably 
codeine, which can be obtained without prescription.” There was little discussion in responses as to 
why doctors might prescribe outside of the guidelines. As with benzodiazepines, the RCPsych noted 
that doctors who lack sufficient training may feel pressurised to continue to prescribe opioids even 
when no clear clinical indication exists; that patients may seek prescriptions from multiple different 
doctors; and that there is an illicit drug market for opiates. In light of the lack of impact of existing 
guidance, the Faculty of Pain Medicine noted that they are working with other stakeholder groups to 
develop consistent advice in the form of a central opioid prescribing resource: “This will be based on 
the evidence regarding the harms and benefits of opioids which prescribers can then draw on to make 
a good clinical decision for an individual patient, influenced of course by the individual's clinical 
presentation, comorbidities and circumstances.” 
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Theme 7: Antidepressants 
Loading themes 
 Antidepressant prescribing 
 Safety of antidepressants 
 Approaches to antidepressant withdrawal 
Points relating to antidepressant prescribing, safety and withdrawal emerged as a distinct theme 
across response submissions. There was a consistent view that antidepressant prescribing is 
increasing, and some consistency that antidepressants can be prescribed without a clear clinical 
need. For example, the RCPsych noted that “...there is potentially overprescribing of these 
medications, particularly SSRIs, where there is no particularly strong clinical indication…”; and CEP 
noted that “[a]ntidepressants are currently indicated in the BNF only for patients with moderate to 
severe depression. Yet withdrawal charities report numerous examples of inappropriate prescribing of 
antidepressants for mild depression.” The latter also highlighted research that in their view does not 
support the use of these drugs for moderate depression, and that the benefits are unclear even in 
cases of severe depression. CITA reported that “[t]here is an increasing use of antidepressants for 
non-depression diagnoses, the prescribing several antidepressants simultaneously within the same 
patient for no apparent sensible reason other than to mask the side effects of each other.”  
There was disagreement between responses on the overall safety of antidepressants, particularly in 
regards to their abuse and dependence potential. Charity and support groups reported that the harm 
associated with antidepressants – including severe mood disturbances, suicidal intention and 
dependence potential – is not generally recognised, or is underestimated, by GPs and psychiatrists. In 
contrast, the RCGP reported that there is “…evidence of the long term benefits of antidepressants 
and the relative safety of their use. Most side-effects and problems occur earlier in treatment and 
there is generally a delay in therapeutic response. Compared to the other medications considered 
[opioids and benzodiazepines] there appears to be a very low prevalence of misuse and addiction.” 
The RCPsych did note that antidepressants carry the risk of a discontinuation syndrome that can be 
unpleasant for the individual, but added that this is not prolonged. CEP highlighted their view that 
the increasing antidepressant prescribing rates reflected the fact that patients are unable to 
discontinue their use due to the onset of withdrawal symptoms, going as far as saying that “…for a 
proportion of patients, BNF prescribing guidelines [of at least 6 months or more, and for at least two 
years for patients with a history of recurrent depression] are leading to involuntary dependence upon 
these drugs. There is no safeguard here; it is a direct consequence of the manner in which these drugs 
have been approved for use.” 
Charity and support groups also felt that antidepressants pose similar levels of harm as 
benzodiazepines, in regards to the severity of side effects and withdrawal, whereas the RCGP and the 
RCPsych reported that antidepressants are safe relative to benzodiazepines and opioids. For 
example, CITA and Recovery Road noted that they have seen a rise in the number of individuals 
contacting them for support for antidepressant withdrawal, which, in their experience, can be as 
severe as benzodiazepine withdrawal. Recovery Road specifically highlighted that “…many doctors 
refuse to acknowledge it [antidepressant withdrawal] exists or even that there is a discontinuation 
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syndrome. This results in patients taking antidepressants being left to self-diagnose and use the 
Internet for support.”  
In relation to this, the RCPsych submitted the 2004 CSM (Committee on Safety of Medicines) review 
on the safety of SSRI antidepressants submitted which provides an overview of research (up to 2004) 
on the relationship between SSRI antidepressants and dependence potential and withdrawal 
reactions. The report concluded that SSRI’s have low abuse liability but that they can cause 
unpleasant withdrawal reactions that should be managed through tapering over a period of several 
weeks. A research recommendation to study the most effective methods for SSRI withdrawal was 
also documented in the report. The RCPsych commented that to their knowledge this research has 
not yet been conducted. 
Where there was agreement that antidepressants are associated with a withdrawal (or 
discontinuation) syndrome, it was also agreed that there is no recognised approach for managing this 
type of withdrawal (discontinuation) syndrome. For example, CITA reported that their experience 
accrued over the years suggests “…that there is no consistent model being applied across and within 
practices…” with regard to antidepressant withdrawal management. CEP specifically noted that BNF 
and NICE guidance are in urgent need of revision as they have conflicting advice on antidepressant 
withdrawal that may contribute towards this inconsistency, which is out of step with the charities’ 
experience working with sufferers. The BNF advises that the dose should be reduced gradually over 
about four weeks, or longer (up to 6 months) for patients on long-term maintenance treatment; 
while NICE advise that antidepressant use can be stopped over a four week period. CEP stated that 
“[t]he experience of the withdrawal charities suggests that antidepressants should be tapered very 
slowly at a rate of no more than 10% of the previous dose every four to six weeks, at a pace guided by 
the patient.  A four-week taper is therefore much too fast, and this guidance should be changed.” In 
consideration of the RCPsych’s comment on the CSM recommendation for research into SSRI 
withdrawal methods, it may be the case that research clarifying what is the best practice to withdraw 
from antidepressants has not been conducted.  
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Concluding remarks 
 
This report identifies various themes relevant to preventing and managing the potential harms 
associated with the prescribed use of benzodiazepines, Z-drugs, opioids and antidepressants. It does 
not provide a detailed examination of every issue highlighted to us, but aims to identify areas of 
agreement and difference, with a view to supporting change. As the majority of submissions focused 
extensively on benzodiazepines, our analysis has a particular emphasis on this drug group; however, 
many of the issues highlighted are relevant across the other drug types. For example, a common 
thread among responses was the need for better training on the safe prescribing and withdrawal of 
these psychoactive medications (including the importance of adherence to prescribing guidelines; 
safe tapering protocols; the risks of long-term use; and providing appropriate support and advice 
before, during and after prescribed use). This is likely to be an important area for action. 
Looking to the future, this analysis identifies areas where there is some common ground among 
stakeholders, such as the need for gradual tapering during withdrawal, the under-funding and poor 
availability of non-pharmacological and psychological treatments, inadequate provision and funding 
of specialised services, and the need for more research. In other areas, however, there are significant 
differences that need to be considered further. For example, a clear view emerged that some 
prescribing guidelines, as well as the views and understanding of medical professionals, do not 
correlate well with the lived experience of patients. This is typified with the differing views on types 
and magnitude of harms associated with prescribed drug dependence and withdrawal, as well as 
attitudes towards the causes of dependence and withdrawal problems. While some of these 
differences may be resolved or reduced through research, changing attitudes and mindsets will 
require a more collaborative approach. 
One example of the need for collaboration is illustrated by how medical organisations have called for 
better guidelines on tapering and withdrawal management for benzodiazepines, while charities and 
supporting groups were broadly of the view that these exist and should already be in use. This 
difference may be explained by the fact that the existing guidelines are expert-based rather than 
having a strong scientific evidence base, and medical professionals may not therefore feel confident 
in using them. Only by working together will such differences in opinion be resolved. 
A further consideration from this analysis is how responses from support groups, charities and 
individuals included an element of 'blame' on doctors (eg for prescribing beyond guidelines or not 
providing adequate information or support), while submissions from medical organisations reflected 
elements of patients being at fault (eg for demanding a 'prescription'), or that some patients may 
become addicted because of particular personal and social factors. It is vital that these perspectives 
do not prevent positive action moving forward.  
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Appendix 1 
Call for evidence questionnaire on involuntary dependence to prescription drugs sent out in March 
2014 
 
The BMA Board of Science is undertaking a project examining ways to support the development of an 
improved policy framework for the prevention, identification and management of involuntary 
dependence to prescription medication. 
As a part of this work the Board is seeking written submissions from key stakeholders. The Board will 
publish a report analysing the submissions. In the longer term, it is planned that the Board will host a 
roundtable meeting with Ministerial representation and other key policy makers, as well as any 
stakeholder organisation party to this agreement. 
Written submissions 
The BMA Board of Science is looking to gather information in relation to the questions set out on 
pages 3-4. Your submission can cover any evidence or perspectives that your organisation considers 
to be relevant, and you do not need to respond to each individual question. The Board will be 
analysing the responses received with a view to publishing a report on the findings from the call for 
evidence. 
All submissions must be accompanied by a statement agreeing to abide by the code of conduct set 
out in the ‘Agreement for collaborative working’ (see Annex 1). The Board will not accept any 
submissions that do not include this accompanying statement. 
Please note: 
- by providing a written submission you are certifying that you are happy for this submission to 
be published in its entirety by the BMA Board of Science 
- the BMA will retain the sole and exclusive rights to produce and publish the findings of the 
call for evidence. 
 
The deadline for submissions is Friday 30 May 2014. 
All submissions should be addressed to the ‘BMA Board of Science’, and sent electronically in 
Microsoft Word file to George Roycroft at groycroft@bma.org.uk.  
Respondents 
Responses are being sought from a range of professional bodies, charities and support organisations 
that the Board has identified as relevant stakeholders. This list is not meant to exclude any 
organisation from responding, so if you feel there is an organisation that is not listed that should be 
invited to contribute, please email groycroft@bma.org.uk  
The Board is willing to accept responses in an individual capacity, and would be happy for your 
organisation to encourage individuals with expertise in this area to provide a written submission in 
accordance with the conditions set out in the ‘Agreement for collaborative working’.  
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Questions 
Background 
As a part of your response, please provide: 
- details of who you are responding on behalf of, including whether it is on behalf of an 
organisation, or in an individual capacity 
- an accompany statement agreeing to abide by the code of conduct set out in the ‘Agreement 
for collaborative working’.  
 
Prescription of medications that have the potential for dependence 
1. Please summarise how and why the following types of medication are currently prescribed, 
including any clinical indicators for prescribing, standard duration of prescription, and any standard 
guidance given / received upon prescription or dispensation: 
- benzodiazepines 
- opioid analgesics 
- z-drugs 
- antidepressants. 
 
NB: please use questions 23 and 24 to provide any comments in relation to other categories of drugs. 
2. Please identify any evidence in relation to the scale, prevalence or trends in the prescribing of the 
medications listed in Question 1. As part of your response please highlight any differences in 
prescribing practices for different patient groups (eg male and female patients, young and elderly 
patients). 
3. Please provide any examples of best practice in the prescription of the medications listed in 
Question 1. 
4. What safeguards exist to protect patients from becoming involuntarily dependent when 
prescribing such medications, how effective are they and what factors limit their effectiveness? 
Non-pharmacological treatments 
5. What non-pharmacological treatments are available for prescription as an alternative to 
prescribing the medications outlined in Question 1? 
6. Are you aware of any data on the availability and uptake of non-pharmacological treatments?  
7. Please identify any examples of best practice in the provision of non-pharmacological treatments. 
Involuntary dependence 
8. Please identify any evidence in relation to the scale, prevalence or trends of involuntary 
dependence to the prescription medications listed in Question 1. 
9. What are the short-, medium- and long-term harms associated with involuntary dependence to 
the medications listed in Question 1? 
10. Please outline the clinical indicators used to identify an individual with involuntary dependence 
to the medications listed in Question 1. 
11. Please summarise any areas of best practice in identifying an individual with involuntary 
dependence to the medications listed in Question 1. 
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Treatment, management and withdrawal 
12. Is the motivation to end the use of the medications listed in Question 1 usually doctor or patient 
led? How are these discussions usually initiated, and is there generally concordance between the 
patient and physician on the clinical rationale for doing so? 
13. For those that are identified as involuntarily dependent on prescription medications what are the 
harms associated with the rapid titration or cessation from prescription medications? 
14. Among involuntarily dependent individuals what is the current approach to treating, managing 
and withdrawing individuals from the medications listed in Question 1? 
15. Are the current approaches to treating, managing and withdrawing involuntarily dependent 
individuals from prescription medications valid? If no, please identify a model process in the 
treatment, management and withdrawal from these medications. 
16. Are there any health concerns for involuntary dependent individuals following the successful 
withdrawal from prescription medications? If so, what are these and how should they be managed? 
Commissioning, provision and standard of treatment services 
17. Please provide an assessment of the commissioning, provision and standard of treatment 
services for involuntarily dependent individuals. 
18. What, if anything, can be done to improve this? 
Governance 
19. Please provide an assessment of the governance of prescribing and treatment services. 
20. What, if anything, can be done to improve this? 
Promoting best practice 
21. What changes (eg educational, training, organisational / structural and policy) are necessary to 
promote best prescribing practices, including non pharmacological treatments? 
22. What changes (eg educational, training, organisational / structural and policy) are needed to 
improve the identification and management of patients affected by involuntary dependence to 
prescription medications? 
Any further information 
23. Are there any additional issues you think the Board should be considering in relation to this 
project?  
24. Do you have any other comments? 
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Appendix 2 
List of organisations and individuals contacted and / or responded to the call for evidence. Responses 
were sought from a range of stakeholders that were identified as relevant. Additional voluntary 
submissions of evidence from relevant organisations and individuals were also accepted as responses.  
Individual/ Organisation 
Response & 
Decline 
Response & 
Submission 
Academy of Medical Royal Colleges   
Addiction Dependency Solutions   
All Party Parliamentary Group for Involuntary Tranquilliser 
Addiction 
  
Association of Anaesthetists of Great Britain & Ireland    
Association of Directors of Public Health   
Battle Against Tranquillisers   
Bristol and District Tranquilliser Project   
British Association for Psychopharmacology   
British Association of Social Workers    
British Dental Association   
British Pain Society    
British Psychological Society    
Centre for Pharmacy Postgraduate Education   
CodeineFree   
College of Social Work   
Committee of General Practice Education Directors   
Conference of Postgraduate Medical Deans of the United 
Kingdom 
  
Council for Evidence-based Psychiatry   
Council for Information on Tranquillisers, Antidepressants, 
and Painkillers 
  
Critical Psychiatry Network   
Faculty of Pain Medicine of the Royal College of Anaesthetists    
General Medical Council   
Medical Schools Council   
National Institute for Health and Clinical Excellence   
National Pharmacy Association   
Oldham Tranx    
Prescribing Observatory for Mental Health   
Public Health England   
Recovery Road   
REST (Mind in Camden)   
RETHINK   
Royal College of General Practitioners    
Royal College of Nursing    
Royal College of Psychiatrists    
Royal Pharmaceutical Society    
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Substance Misuse Management in General Practice   
The Bridge Project   
The Samaritans   
               Additional Responses 
Anonymous self-help group   
BenzoBuddies   
Catherine Pittman   
David Dicks   
Heather Ashton   
Howard Wingfield   
NHS Greater Glasgow & Clyde Managed Clinical Network for 
chronic pain 
 
 
NHS Greater Glasgow & Clyde Management Addiction 
Services 
 
 
Royal College of Physicians   
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Appendix 3 
Further details of the analysis process 
During the early stages of analysis, it was identified that the data fell into two categories: (1) 
qualitative codeable data and (2) qualitative non-codeable data. Data from group one consisted of 
qualitatively rich data from questionnaire responses, and long transcripts of an opinion or 
experience. Data from group two consisted of published guidelines, journal articles, webpages and 
short summaries of opinion. The latter type of data are not appropriative for systematic coding as 
they have either already been systematically reviewed (published articles and guidance), or are in an 
incompatible format to code reliably (websites, short summary).  
To include all responses on this topic into an analysis, the analysis was conducted in two phases. 
Phase one employed a thematic analysis within each individual submission from group one. Each 
submission was systematically coded followed by an analysis of all codes into broader level themes. 
This created a list of overarching themes per response submission. All themes per submission were 
then collated and analysed together to generate a final list of broad themes that represented 
information and views across all submissions from group one.  
Phase two involved analysis of submissions from group two. As the content of these submissions 
were not applicable to coding, key points within each response were extracted, collated and 
contrasted against the overall themes finalised from phase one. This allowed submissions of 
evidence in a non-codable format, from Group 1 and 2, to be equally represented within final 
themes. A set of themes incorporating all evidence submissions were then finalised. A step-by-step 
guide of this analysis is outlined in the following table. 
Step by step guide of analysis procedure 
Phase Data Step Method 
1 Group 1 1 Systematic codes applied per response submission 
2 Codes analysed into themes per response submission 
3 All themes per response collated and analysed into 
final themes that represent the information and views 
from group 1 
2 Group 2 
 
 
Group 1&2 
4 Key points extracted per individual submission 
5 Key points are reviewed in contrast to key themes 
identified at step 3. 
6 Final list of themes that represent the information and 
views from groups 1 & 2. 
 
  
 34 
 
Appendix 4 
Individual themes per submission (Group 1) 
Organisation Individual submission themes Final theme number 
Anonymous 
Self-Help Group 
1. Inconsistent guidance & standards on how to 
manage BDZ withdrawal management. 
2. Rapid tapering, withdrawal & harms. 
3. Violation of patient and human rights by current 
management. 
4. Lack of government responsibility. 
1 
 
1 and 3 
1 and 4 
 
2 
Battle Against 
Tranquillisers  
1. Current approach by doctors: 
Prescribing outside of guidelines (BDZ & Z-drug) 
Inconsistent approach to managing withdrawal  
Cut patients too quickly 
Lack of patient centred approach 
GPs need better education and training on BDZs 
Primary care needs better safeguards to monitor 
automated repeat prescriptions. 
2. Service standards and provision: 
Better integration needed between primary care 
and support services 
Services not standardised across different care 
settings (especially prisons) 
Specialised services that are required at a local 
level that are well trained and staffed  
Stronger central drive for services needed. 
3. Harms associated with rapid tapering from BDZ 
and withdrawal: 
Range of physical, psychological and social harms 
Patient forced to buy illegally 
Suicide. 
4. Guidance: 
BNF guidance not followed 
PHE commissioning guidance not followed 
Inconsistent guidance on withdrawal 
management. 
5. Trends in prescribing: 
Antidepressants 
Opioids 
Z-drugs. 
6. Moral arguments: 
Terminology of ‘involuntary’ is misleading 
GPs given incentives to cut patient prescriptions 
Violation of patient and human rights 
Violation of NHS constitution  
Violation of Equality and Diversity Act 2010 
1 
 
 
 
 
 
 
 
 
2 
 
 
 
 
 
 
 
 
3 
 
 
 
 
1 and 2 
 
 
 
 
 
7 
6 
1 
     4 
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BenzoBuddies 1. BDZ prescribing and withdrawal methods: 
GPs prescribe outside of guidelines 
GPs withdraw patients too quickly against their 
wishes (not patient centred) 
GPs often do not have good knowledge and 
understanding of BDZ and withdrawal severity 
Patients often not informed and misinformed of 
risk of dependence and withdrawal severity 
GPs often can’t distinguish between BDZ 
withdrawal and psychiatric symptoms 
Patients are often unsupported and abandoned 
by their GP once dependence is identified. 
2. BDZ side effects and harms (general): 
Tolerance, dependence and withdrawal (short, 
medium and long-term side effect and risk) 
Withdrawal severity increases with long-term 
use 
Withdrawal includes severe physical (seizures, 
stroke), psychiatric (anxiety, suicide), 
psychological (behaviour changes, emotional and 
motivational blunting), personal (loss of 
relationships) and social (job/ educational loss) 
symptoms. 
3. Severe psychiatric symptoms in patients with no 
psychiatric history: 
No difference in withdrawal symptoms between 
patients with and without psychiatric history 
Emotional blunting, long-term anxiety, PTSD, risk 
of suicide and need for long-term psychological 
support experienced by non-psychiatric patients 
4. Protracted and longer-term side effects: 
Symptoms of withdrawal can continue for up to 
5-6 years 
There can be protracted physical (headaches), 
psychiatric/ psychological (anxiety, depression, 
risk of suicide with failed tapering attempts, 
PTSD, relapse), personal (loss of friendships) and 
social (lost job/ missed education) 
5. Rapid tapering and withdrawal side effects: 
Rapid tapering causes more severe withdrawal 
that is usually intolerable and causes relapse 
Greater risk of suicide as withdrawal is 
intolerable 
1 and 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
 
 
 
 
 
 
 
 
 
 
4 
 
 
 
 
 
 
 
3 
 
 
 
 
 
 
 
 
3 
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Greater chance of tapering failure and relapse 
Greater protracted harm 
6. Service provision: 
No specialised services for these patients – only 
inappropriate addiction services for illicit users  
Greater number of alternative therapies needed 
(counselling, CBT, social therapies). 
 
 
 
2 
 
 
 
 
 
Bristol 
Tranquilliser 
Project 
1. Doctors current approach to BDZ and AD 
prescribing, dependence and withdrawal 
management: 
Prescribe outside of guidelines 
Lack of patient information on harms 
Lack of safeguards (AD) 
Poor knowledge and training on BDZ and AD, 
underestimate WD, unaware of AD dependence 
and WD 
Sometimes deny harms 
Fixed tapering not patient centred or flexible 
Lack of alternative therapies. 
2. Harms associated with BDZ and AD: 
Long-term damage associated with BDZs 
(anxiety, depression, confusion, insomnia) and 
AD (mania, sense of loss of self, emotional 
blunting) 
BDZ and AD withdrawal symptoms are similar 
(anxiety, suicidality, desperation, terror, 
confusion, insomnia) 
BDZ and AD withdrawal can be protracted for up 
to several years 
Rapid BDZ tapering – seizures, psychosis, suicide. 
3. Specialist services and Government action: 
Few alternative therapies to medication  
No valid treatment services – urgent need for 
specialised services 
Overreliance on charities to support these 
patients 
Government makes promises but does not action 
new services. 
 
1 and 7 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 and 7 
 
 
 
 
 
 
 
 
 
 
 
2 
Catherine 
Pitman 
1. Harms associated with BDZ dependence: 
Long-term harms and duration of protracted 
withdrawal – on average up to 14 months after 
completed withdrawal 
3 
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No difference in the number of psychiatric 
symptoms experienced in withdrawal between 
individuals with a history of psychiatric diagnosis 
and those without. 
Council for 
Evidence Based 
Psychiatry 
1. Harms associated with psychoactive drugs: 
BDZ and AD are associated with a multitude of 
physical, psychiatric, psychological and social 
harms which increase with long-term prescribing 
The risk to benefit ratio of BDZ and AD in regards 
to the magnitude of these harms needs better 
consideration when prescribing. 
2. Lack of research and data on: 
The prevalence of BDZ and AD dependence 
The prevalence of long-term prescribing  
Harms associated with long-term prescribed use 
of BDZs and ADs. 
3. Current approach by doctors to prescribing BDZ 
and ADs:  
BDZs are over-prescribed outside of guidelines 
that exist to regulate this 
AD are over-prescribed as a direct result of 
guidelines that encourage inappropriate long-
term prescribing (eg. BNF recommends 
prescribing up to two years for recurrent 
depression) – such guidelines need updating 
Training – doctors (mainly GPs) do not have 
adequate training on the harms associated with 
BDZs and AD dependence or how to appropriately 
manage withdrawal 
Risk of misdiagnosis due to lack of training on 
dependence and withdrawal 
Alternative non-pharmacological therapies should 
be considered for longer-term approaches for 
treatment. 
4. Poor service provision 
There should be national mandatory provision of 
prescribed drug withdrawal services 
There is a moral obligation for the NHS to provide 
services for these patients. 
 
3 
 
 
 
 
5 
 
 
 
1 and 7 
 
 
 
 
 
 
 
 
 
 
 
2 and 4 
Council for 
Involuntary 
Tranquilliser 
Addiction 
1. Healthcare professionals (mainly GPs) 
knowledge or understanding of prescription drug 
dependence: 
Denial of drug induced harm 
Poor monitoring 
Treat patient as an illicit drug user 
Lack of patient centred approach 
Usually no long-term plan when prescribing 
Drugs viewed as cure rather than temporary 
respite. 
1 
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2. Attitudes towards prescription drug dependence 
as illicit drug dependence: 
Doctors (mainly GPs) blame patients for their 
dependence 
Funds for this patient group are pooled with illicit 
drug treatment services. 
3. Poor service provision: 
Lack of appropriate services that are separate to 
illicit drug treatment services. 
4. Antidepressants: 
Prescribing increased dramatically in recent years  
Often prescribed without clear clinical indication 
GPs deny harms 
Symptoms associated with AD withdrawal are 
similar to BDZ withdrawal 
No consistent approach to managing AD 
withdrawal. 
 
4 
 
 
 
 
 
 
2 
 
 
7 
 
David Dicks 1. Let down by medical professionals (GPs, 
psychiatrists and psychologists): 
Given incorrect information for over 27 years 
Not supported by healthcare professionals 
2. Multiple long-term harms associated with long-
term prescribing: 
Physical (IBS, headaches, dizziness etc), 
psychiatric (anxiety, depression, insomnia etc.), 
psychological (suicidal thoughts, isolation, loss of 
friendship networks) and social (work 
impairment, lost job). 
    Long-term harms – medication “…had ruined my 
life”. 
3. Integrated and patient centred model of care is 
best approach/ practice: 
“If it had not been for the teamwork between my 
doctor, Battle Against Tranquillisers and myself I 
would not have come off.” 
4. Endogenous vs iatrogenic condition 
Told for 27 years that he was the cause of all my 
symptoms and that the symptoms were not a 
result of BDZs.  
1 
 
 
 
3 
 
 
 
 
 
 
 
1 
 
 
 
 
4 
Heather Ashton 1. Poor central governance and appropriate service 
provision: 
DH approach involves inertia and ignorance 
DH does not taking responsibility or action 
Virtually no provision of appropriate services for 
this patient group.  
Services should be separate from illicit drug 
treatment services. 
2. Lack of research on the scale of BDZ dependence 
and long-term prescribing. 
2 
 
 
 
 
 
 
 
5 
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3. Illicit misuse vs iatrogenic condition: 
Patients consistently viewed and treated as illicit 
drug misusers. 
4. Harms associated with BDZ dependence:  
Multiple severe harms spanning physical, 
psychiatric, psychological and social harms 
Rapid tapering causes severe harm to patients. 
 
4 
 
 
3 
Howard 
Wingfield 
1. Poor central governance and service provision: 
There is little to no provision of appropriate 
services for this patient group. 
DHs provides false information on national 
service provision 
DH deny and refuse to recognise the scale of the 
problem. 
2. The scale and magnitude of harms associated 
with prescription BDZ dependence: 
Harms span physical, psychological (stress, 
isolation) and social (job loss, financial strain) 
harms. 
3. Attitudes towards prescription dependence as 
illicit dependence: 
There is a misconception that prescription drug 
dependence is the same as illicit drug misuse 
Different type of dependence that needs separate 
treatment to illicit drug misuse 
4. Lack of research into the harms associated with 
long-term prescribing of BDZs. 
5. Doctors (GPs and psychiatrists) approach: 
Enforce rapid tapering despite the associated 
harms 
Better education and training is needed for 
healthcare professionals at all levels, but 
particularly GPs  
Best practice examples include Oldham Tranx and 
Ashton Manual. 
 
2 
 
 
 
 
 
 
3 
 
 
 
 
4 
 
 
 
 
 
5 
 
1 
NHS GGC 1. Managing opioid dependency: 
Opioid dependency that has developed following 
prescribing for chronic pain is currently managed 
by an ‘illicit model’ of treatment. 
2. Opioid related harms and trends: 
Increase in prescription opioid related deaths 
Increase in dependence to OTC opioids – 
guidelines should be updated to include over the 
counter opioid dependency. 
3. Models of best practice when prescribing opioids 
for chronic pain: 
Patient centred – patient must be informed of the 
risk of dependence 
4 and 6 
 
 
 
3 and 6 
 
 
 
 
6 
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Long-term plan for prescribing with clear end 
point 
Opioid trial 
Regular review and monitoring 
Joined up local services. 
 
RCGP 1. GP training, support and resource for primary 
care: 
Lack of services commissioned for this patient 
group that GPs can refer patients onto 
GPs may feel that they do not have the skills and 
confidence to support these patients (often 
involves reducing prescription against patient 
wishes which requires a lot of discussion and can 
compromise doctor patient relationship) 
GPs need enhanced education in this area and 
need more time allocated to improve local 
services 
Alternative non-pharmacological treatments are 
not usually available to refer patients to instead 
of prescribing drugs 
Confusion over what is best practice in this area. 
2. Causes for long-term prescribing, inadvertent 
prescribing and dependence: 
Patient pressures 
The nature of mental health and pain leads to 
inadvertent prescribing because patients need 
long-term support 
There are only a small number of individuals who 
are vulnerable to, and go on to, develop 
dependence. 
3. Harms/ safety of prescription drugs with 
dependence potential: 
BDZ and opioid dependence is associated with a 
number of physical, psychological and social 
harms  
Overall BDZ and opioids are well tolerated by the 
body and do not cause any long-term injury 
ADs are safe in comparison to BDZ and opioids 
ADs have low abuse liability 
No evidence AD can lead to long-term injury or 
harm. 
 
1 and 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 and 4 
 
 
 
 
 
 
 
 
 
3, 5, 6 and 7 
 
 
 
 
 
 
 
 
 
 
PHE 1. Published guidance: 
PHE commissioning guidance, BNF and NICE 
2. Service provision: 
Examples of best practice – the Bridge, 
Manchester, Liverpool, The Wirral. 
2 
 41 
 
RCPsych 1. Currently there is long-term, high-dose 
prescribing of BDZs outside of guidance, reasons 
for this include: 
Poor prescribing safeguards 
Lack of alternative non-pharmacological services 
available 
Growing illicit market that drives demand 
Lack of appropriate training for doctors 
(particularly GPs) on prescription dependence 
Patients conceal the magnitude of their use so 
doctors do now know the full scale of their use 
Lack of clinical guidance on how to monitor, 
detect and screen for dependence and what is 
best practice for managing dependence  
Irresponsible prescribing 
Patient pressures (particularly on GPs) 
2. Poor governance and commissioning of 
appropriate services 
Not a priority area for policy makers or 
commissioners 
Unserved population that fall between general 
psychiatry and addiction services 
Addictions services for illicit drug use do not have 
the skills to support this patient group 
Addiction services are dissuaded from seeing this 
patient group 
No services to support inpatient detox 
A commissioning guideline that is separate from 
illicit drug use should be developed for this area.  
3. Associated harms 
BDZ and opioids – short-term use there are few 
harms 
BDZ and opioids – long-term use can lead to 
dependence, withdrawal syndrome. 
4. Lack of research and data in this are: 
Need better data on the prescribing patterns and 
the prevalence of perception dependence to 
identify what is legitimate prescribing and what 
isn’t (currently being undertaken by KCL) 
Need for research is needed to clarify what is the 
best approach to managing prescription BDZ 
dependence and withdrawal.  
5. Antidepressants: 
ADs are potentially overprescribed for mild 
depression where there isn’t strong clinical 
indication 
AD have a low abuse potential and are therefore 
generally a safe drug 
AD do have a discontinuation syndrome but this 
can be easily managed if slow tapering is 
employed. 
1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 and 6 
 
 
 
5 
 
 
 
 
 
 
 
7 
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Recovery Road 1. Doctors approach and knowledge to BDZ and AD 
dependence: 
The biggest contributor to this problem is doctor’s 
(mainly GPs but also psychiatrists) lack of 
knowledge on prescription dependence 
There is guidance on safe cutting from BDZs (eg 
BNF, NICE, Ashton manual etc) but it is not 
followed by doctors 
Doctors do not know how to identify dependence 
in patients  
Doctors do not know how to support patients 
through withdrawal (usually cut too quickly) 
Doctors underestimate the full extent of harms 
associated with dependence and withdrawal. 
2. Harms: 
Rapid tapering  
Multiple harms spanning physical, psychiatric, 
psychological and social harms. 
3. Antidepressants: 
Prescribing is increasing 
Often prescribed without strong clinical indication 
AD withdrawal is similar to BDZ and Z-drug 
withdrawal 
Doctors refuse to acknowledge that AD 
withdrawal exists and the harms associated with 
this. 
4. Poor service provision: 
No provision of specialist services or standards of 
services for this group 
Lack of alternative therapies for this group. 
 
1 and 7 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
 
 
 
7 
 
 
 
 
 
 
 
2 
REST 1. Doctors (GPs) approach and knowledge on BDZs: 
Do not inform patients of the associated risks or 
alternative therapies 
Treat patients as illicit drug users 
Do not refer onto specialists 
Underestimate the severity of withdrawal  
Lack of a patient centred approach 
2. Harms associated with BDZ dependence and 
withdrawal: 
Harms while on drug and longer term (protracted 
withdrawal) include – changes to cognitive 
function, physical dependence, Illicit use, relapse, 
motional blunting, anxiety, panic attacks, 
tolerance, cravings, sleep difficulties, 
psychological harms (loss of self esteem ‘why me’, 
trauma of years of life lost to drug dependency) 
and social harms (job loss, friends and family 
relationship loss) 
Rapid tapering 
1 
 
 
 
 
 
 
3 
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Most severe withdrawal harms including suicide, 
seizures, hallucinations and psychosis 
BDZ withdrawal is short and long-term harm 
Many symptoms of withdrawal persist into 
protracted withdrawal long-term. 
3. Poor service provision: 
Virtually no provision of specialist services or 
alternative to services to GP 
No funding for specialist alternative services 
Specialist services should be commissioned for 
this patient group that include counselling and 
social support groups. 
4. Client profile: 
Majority do not take illicit drugs. 
5. Lack of research and data on the scale of BDZ 
dependence. 
 
 
 
 
 
 
2 
 
 
 
 
 
 
4 
 
5 
Royal 
Pharmaceutical 
Society 
1. Better information sharing/ integrated models of 
health services (including pharmacists) are 
required to build effective safeguarding systems 
to prevent and identify dependence to 
prescription medicines. 
2 
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Appendix 5  
Key themes extracted from individual submissions (Group 2) 
Organisation Key points Final theme 
number 
Royal College of 
Physicians 
 
1. There are rising concerns about prescribing opioids 
for chronic non-cancer pain. 
2. Lack of data to make strong evidenced based 
recommendations from despite current 
widespread use. 
3. Lack of data: 
More studies are need that evaluate the short and 
long-term harms/ benefits of different prescribing 
patterns. 
5 and 6 
Faculty of Pain and 
the Royal College of 
Anaesthetists  
 
1. Existing guidance on opioid prescribing from 
chronic non cancer pain not being followed. 
6 
Chronic Pain 
Managing Clinical 
Network Greater 
Glasgow & Clyde 
1. Lack of robust local integrated services available to 
manage pain and dependency 
2. Scale of opioid prescribing for chronic non-cancer 
pain – there is increasing prescribing of opioids for 
chronic pain and associated mortality is increasing. 
Morbidity leading to mortality. 
2 and 6 
NHS Greater Glasgow 
& Clyde Addition 
Services 
 
1. Existing guidelines focus on an illicit model of 
dependence, and management is focused around 
this. 
4 and 6 
 
